Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing - Wikidata - awgldk - TriplyDB

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

http://www.wikidata.org/entity/Q34052814

about

Genome-editing Technologies for Gene and Cell Therapy Toward more predictive genetic mouse models of Alzheimer's disease Towards a new era in medicine: therapeutic genome editing Engineered Viruses as Genome Editing Devices Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation Therapeutic genome editing: prospects and challenges CRISPR-Cas9 knockin mice for genome editing and cancer modeling Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.CRISPR/Cas9 Immune System as a Tool for Genome Engineering.Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot.The history and market impact of CRISPR RNA-guided nucleases.Precision cancer mouse models through genome editing with CRISPR-Cas9.Development of an intein-mediated split-Cas9 system for gene therapy Applications of CRISPR technologies in research and beyond.Genetics of coronary artery disease: discovery, biology and clinical translation.Regenerative medicine: targeted genome editing in vivo.In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling.Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications.The Use of Induced Pluripotent Stem Cells for the Study and Treatment of Liver Diseases.CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.A CRISPR Path to Engineering New Genetic Mouse Models for Cardiovascular Research The CRISPR/Cas9 system for gene editing and its potential application in pain research Human-induced pluripotent stem cell approaches to model inborn and acquired metabolic heart diseases.CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.The CRISPR/Cas9 System and the Possibility of Genomic Edition for Cardiology Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.Selection of DNA aptamers with two modified bases.Beyond traditional pharmacology: new tools and approaches.CRISPR genome engineering and viral gene delivery: a case of mutual attraction.CRISPR-Cas9: a new and promising player in gene therapy.Prospect and progress of gene therapy in treating atherosclerosis.Modeling Disease In Vivo With CRISPR/Cas9.Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics.Human Germline Genome Editing.Optogenetics enlightens neuroscience drug discovery.

P2860

Q26769662-E14A8A2D-E25A-4C13-A10F-788763B620A0 Q26771883-7F2DB764-9CB7-4019-8B27-23BCC5034239 Q26773287-9E4610DF-2330-4FA9-B043-CB2FA4F8D00C Q26785927-12AE0B5C-5241-48A3-9E59-D01C042E46F6 Q26799437-55B49225-A0B1-485E-80D8-9A5CFA23F6F5 Q28087380-849DAFBF-FE56-4AE5-A770-24BF0DBECFCA Q30607892-D8091E06-F0C2-4533-B7CE-D20D928CDCEA Q33599961-23DF2C22-6B0D-41CD-A1C7-BAB7D427C537 Q33695238-4709FFBE-5A51-4E95-9959-17B627C29F0C Q34063943-5AB622D9-5008-4071-8288-40C8BA6AC7CD Q34473680-1B05F716-8DAE-4D69-B1A3-B96BF6EC4F98 Q34480103-5C634500-A8BC-40B9-8758-A6A9F56B820A Q34481059-310107B2-E7AF-4D16-AB18-6373E7025C44 Q34539796-D1869903-DC02-4EA4-8459-64DFAD6124B9 Q34553141-D5A9D8B3-B380-44EA-B67B-7E00253445CF Q35146211-A14716A4-0860-4B8D-9582-17CB80047253 Q35820051-86DAFA9E-23D0-48D2-A5FD-ACCC01EB0B93 Q35871626-1020862A-AF26-44F7-8ABC-48663DF35578 Q36035643-4DCAB7D7-23A8-4D07-AF4C-3310C6D5D4AE Q36245097-A400F55C-55CA-4B96-971A-F1A00167EFE9 Q36412556-9A9FB5CD-A2C6-4F5E-99C8-013D9F7BC54D Q36675277-B4C6EAD8-9DB3-44A6-8C55-1D8884902935 Q36695546-666A444B-5440-4697-BB0C-4503CE266E59 Q36849517-FAB0D44B-37A2-4D4F-906A-E630E9C5B0B9 Q36940626-73DA288A-D783-4860-B673-7B077F632F3B Q37148023-88EC32C3-462C-4A62-B463-5BBCF06317C3 Q37153107-D56B46A7-2C7F-49A7-9AE7-7BC95F6F990E Q37446641-247911CB-8246-4556-96D4-A51554709427 Q37559174-93C718B7-609A-4ECF-BA7B-07738259AC17 Q37594531-0660E553-1745-40E0-B02E-D4414E283A12 Q37688760-AC1CDBB7-95E6-4B34-9113-60FFF57E5FB8 Q37711632-D06E1135-AC2E-4986-862E-C77BDF8FF47E Q38311702-97654AD2-57F7-4365-A00F-53CFF9ADE6C1 Q38348602-7AAF9915-C675-45F1-AFF1-B14262096E06 Q38364993-55E73A4C-2206-4BBC-88ED-E9CC717CFA3D Q38578275-A300FA70-D057-4CFA-8C6D-2D6480B0EBFB Q38598073-62262169-24F1-41F3-A7DB-67C6BDCA6A1F Q38637555-65C73009-0B08-4A65-B222-8568D24EDE54 Q38646763-8E9ABEC1-81C7-44BB-8971-BABAAA8800C1 Q38650124-7EC081AA-4064-4C99-8CED-647A70CFF4BA

P2860

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

http://www.wikidata.org/entity/Q34052814

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@ast

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@en

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@nl

type

label

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@ast

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@en

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@nl

prefLabel

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@ast

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@en

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@nl

P1433

Q34052814-373062C0-07D8-449B-9B3D-98D64C864FD5

P1476

Q34052814-38D507C3-7D56-4B16-922E-1CE5C5F592D5

P2093

Q34052814-0F28B198-5586-4312-9146-9FED55F68B43

Q34052814-25DBF93B-4B50-4AD7-9779-7CBB54C6AD26

Q34052814-2784F8B9-A027-4EE6-900B-AA941AD912AA

Q34052814-871BA18C-20CF-4895-839B-71E8A07A8642

Q34052814-9202DBAC-CBE1-49E8-BA9D-E4983571C6DD

Q34052814-C0346831-6A63-46D5-AB54-4AA95E4E5D94

Q34052814-E4DADED9-34FF-4B04-8E39-A000EEC273A4

Q34052814-E853D985-267D-4A1D-8B1E-08AFEE0D9162

Q34052814-FA8900CD-D820-4521-ADD1-E552AB5C0BC3

P2860

Q34052814-11036482-5F1E-467A-A907-E6DE8050145B

Q34052814-2945577C-95C1-462B-9A08-D14BFEB6100C

Q34052814-36D8FA20-A0D4-4ADB-A866-1BA91E98A61A

Q34052814-4044F852-3FF0-44F5-B921-349FD80E4FFD

Q34052814-4E6E7F47-D019-41F3-8740-F335CF173D78

Q34052814-5233C0C4-FA5A-4D85-9705-92721A00527E

Q34052814-72A5338E-C64D-4C02-BEFB-65DCAC070852

Q34052814-AC4C25A6-F27E-45AD-9FD2-7E133C3AA31C

Q34052814-AE223110-39D0-4746-8C3F-0D9C62350593

Q34052814-F32D1F34-2F75-4BAB-A168-916B798C56FF

P304

Q34052814-11A78CC3-0295-43D0-878F-47556235397A

P31

Q34052814-0D2A2398-B403-44D3-945E-E7012B6513E5

P356

Q34052814-B94ED094-89E4-4EB9-9497-DF681306298E

P433

Q34052814-644A072F-FD14-46AD-9280-022E864B3F40

P478

Q34052814-C236882C-43AB-4A77-BEF2-9CA0CB979A14

P577

Q34052814-17BF7682-6578-433E-A75F-D9C29D7B8959

P698

Q34052814-13CD146A-5614-4B23-A630-31EFC2A572B9

P921

Q34052814-86E6DF08-F244-4C7E-9CF2-3B3625A0CB87

P932

Q34052814-19C1141D-7427-490C-BBE6-C5252984BAD6

P356

CIRCRESAHA.115.304351

P1433

Circulation Research

P1476

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing

@en

P2093

Alanna Strong

http://www.w3.org/2001/XMLSchema#string

Bridget S Gosis

http://www.w3.org/2001/XMLSchema#string

Chad A Cowan

http://www.w3.org/2001/XMLSchema#string

Daniel J Rader

http://www.w3.org/2001/XMLSchema#string

Kevin M Patel

http://www.w3.org/2001/XMLSchema#string

Kiran Musunuru

http://www.w3.org/2001/XMLSchema#string

Qiurong Ding

http://www.w3.org/2001/XMLSchema#string

Stephanie N Regan

http://www.w3.org/2001/XMLSchema#string

Sze-Ling Ng

http://www.w3.org/2001/XMLSchema#string

P2860

RNA-guided human genome engineering via Cas9

Multiplex genome engineering using CRISPR/Cas systems

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype.

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.

P304

488-492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCRESAHA.115.304351

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24916110

http://www.w3.org/2001/XMLSchema#string

P921

P932

4134749

http://www.w3.org/2001/XMLSchema#string